Literature DB >> 2238303

Influence of high-energy shock waves and cisplatin on antitumor effect in murine bladder cancer.

K E Lee1, P Smith, A T Cockett.   

Abstract

The potential application of high-energy shock waves (HESW) for control of experimental bladder cancer was investigated. Subcutaneous 3-d murine bladder cancer (MBT-2) in C3H mice were exposed to HESW alone (250 to 1,500 shocks) or in combination with cisplatin (5 to 10 mg/kg, i.p.). Although HESW alone showed no influence on tumor growth, HESW/cisplatin combination therapy suppressed tumor growth more than cisplatin alone. Subsequent studies revealed that an air-fluid interface relative to tumor location played a pivotal role for the chemosensitizing effect of HESW. HESW treatment was able to enhance the cisplatin cytotoxicity only when the tumors were placed adjacent to the air-fluid interface.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2238303     DOI: 10.1016/s0090-4295(90)80292-u

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  5 in total

1.  Transient increase in membrane permeability of L1210 cells upon exposure to lithotripter shock waves in vitro.

Authors:  S Gambihler; M Delius
Journal:  Naturwissenschaften       Date:  1992-07

2.  In vitro interaction of lithotripter shock waves and cytotoxic drugs.

Authors:  S Gambihler; M Delius
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

3.  The combined effects of high-energy shock waves and cytostatic drugs or cytokines on human bladder cancer cells.

Authors:  K Wörle; P Steinbach; F Hofstädter
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 7.640

4.  Mechanism of anti-tumor effect of combination of bleomycin and shock waves.

Authors:  M Kato; N Ioritani; T Suzuki; M Kambe; Y Inaba; R Watanabe; H Sasano; S Orikasa
Journal:  Jpn J Cancer Res       Date:  2000-10

5.  High-energy underwater shock wave treatment for internal iliac muscle metastasis of prostatic cancer: a first clinical trial.

Authors:  S Hoshi; S Orikasa; K Suzuki; T Saitoh; T Takahashi; K Yoshikawa; M Kuwahara; M Nose
Journal:  Jpn J Cancer Res       Date:  1995-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.